# Olaparib, Cediranib Maleate, and Standard Chemotherapy in Treating Patients With Small Cell Lung Cancer

> **NCT02899728** · PHASE2 · TERMINATED · sponsor: **National Cancer Institute (NCI)** · enrollment: 9 (actual)

## Conditions studied

- Extensive Stage Lung Small Cell Carcinoma

## Interventions

- **DRUG:** Carboplatin
- **DRUG:** Cediranib
- **DRUG:** Cediranib Maleate
- **DRUG:** Cisplatin
- **DRUG:** Etoposide
- **DRUG:** Olaparib

## Key facts

- **NCT ID:** NCT02899728
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2018-03-30
- **Primary completion:** 2020-03-17
- **Final completion:** 2020-03-17
- **Target enrollment:** 9 (ACTUAL)
- **Why stopped:** Inadequate accrual rate
- **Last updated:** 2023-10-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02899728

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02899728, "Olaparib, Cediranib Maleate, and Standard Chemotherapy in Treating Patients With Small Cell Lung Cancer". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT02899728. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*